Clinical Scorecard: Metabolic Modulation and Immune Suppressive Roles of Lipid-Associated Macrophages in Pancreatic Ductal Adenocarcinoma

At a Glance

Key Highlights

• LAMs are characterized by co-expression of TREM2, APOE, CD9, and lipid-handling genes.
• Accumulation of LAMs correlates with poor prognosis in PDAC.
• LAMs undergo metabolic rewiring that enforces an immunosuppressive phenotype.
• Preclinical targeting of CD36, TREM2, or fatty acid oxidation shows promise.
• Challenges include toxicity and delivery of therapeutic strategies.

Guideline-Based Recommendations

Diagnosis

• Identification of LAMs as a distinct subpopulation of tumor-associated macrophages in PDAC.

Management

• Consider targeting metabolic pathways involving LAMs for therapeutic intervention.

Monitoring & Follow-up

• Monitor LAM accumulation as a potential prognostic marker in PDAC.

Risks

• Potential toxicity and delivery challenges associated with targeting LAMs.

Patient & Prescribing Data

Patients diagnosed with pancreatic ductal adenocarcinoma.

Emerging research on immune checkpoint molecules may help overcome resistance to current therapies.

Clinical Best Practices

• Utilize single-cell RNA sequencing to explore TAM heterogeneity.
• Focus on developing tumor-selective delivery systems for therapies targeting LAMs.
• Validate biomarkers for patient stratification in clinical trials.

Related Resources & Content

• GLOBOCAN 2020 Data
• Jaitin et al. 2019 Study
• Zhang et al. Recent Work